OncoTargets and Therapy

Journal Information
ISSN / EISSN : 11786930 / 11786930
Current Publisher: Dove Medical Press Ltd. (10.2147)
Total articles ≅ 3,905
Current Coverage
SCOPUS
PUBMED
PMC
SCIE
DOAJ
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Chunxiu Liu, Hu Zhang, Hui Liu
Published: 11 October 2019
OncoTargets and Therapy, Volume 12, pp 8455-8466; doi:10.2147/ott.s215819

Abstract:Long Noncoding RNA UCA1 Accelerates Nasopharyngeal Carcinoma Cell Progression By Modulating miR-124-3p/ITGB1 Axis
Published: 11 October 2019
OncoTargets and Therapy; doi:10.2147/ott

Abstract:An international, peer-reviewed journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. In terms of therapy, palliative care is also included as part of the overall patient care process.
Shuyu Zhai, Yuanbin Liu, Xiongxiong Lu, Hao Qian, Xiaomei Tang, Xi Cheng, Yue Wang, Yusheng Shi, Xiaxing Deng
Published: 9 October 2019
OncoTargets and Therapy, Volume 12, pp 8287-8299; doi:10.2147/ott.s223221

Abstract:INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT
Chen Xia, Hong Jiang, Fugui Ye, Zhigang Zhuang
Published: 8 October 2019
OncoTargets and Therapy, Volume 12, pp 8319-8328; doi:10.2147/ott.s218524

Abstract:The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer
Ning An, Haoyi Wang, Ji Li, Xiaoyang Zhai, Wang Jing, Wenxiao Jia, Li Kong, Hui Zhu, Jinming Yu
Published: 8 October 2019
OncoTargets and Therapy, Volume 12, pp 8311-8318; doi:10.2147/ott.s223216

Abstract:Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
Can Shi, Yijun Yang, Lei Zhang, Juanpeng Yu, Shanshan Qin, Hongge Xu, Yingchun Gao
Published: 8 October 2019
OncoTargets and Therapy, Volume 12, pp 8329-8338; doi:10.2147/ott.s220339

Abstract:MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9
Li Yao, Linghui Zhou, Yujiao Deng, Yi Zheng, Pengtao Yang, Meng Wang, Shanshan Dong, Qian Hao, Peng Xu, Na Li, et al.
Published: 7 October 2019
OncoTargets and Therapy, Volume 12, pp 8241-8247; doi:10.2147/ott.s221204

Abstract:Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study Li Yao,1,* Linghui Zhou,2,3,* Yujiao Deng,2,3,* Yi Zheng,2,3 Pengtao Yang,2 Meng Wang,2 Shanshan Dong,4 Qian Hao,2,3 Peng Xu,2,3 Na Li,2,3 Ying Wu,2,3 Zhen Zhai,2,3 Lijuan Lyu,2,3 Zhijun Dai2,3 1Department of Neurology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 2Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 3Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China; 4School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhijun DaiDepartment of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, People’s Republic of ChinaEmail [email protected]: Thymidylate synthase (TYMS) polymorphisms are reported to be related to susceptibility to some cancers. However, no study exists on TYMS polymorphisms and glioma risk. This study aimed to evaluate the relationship between two common TYMS gene variants (rs1059394 C>T, rs2847153 G>A) and glioma susceptibility.Methods: This case-control study included 605 patients and 1300 cancer-free individuals. Genotyping was performed using Sequenom Mass-ARRAY. We determined odds ratios (ORs) and their 95% confidence intervals (CIs) to estimate the correlations.Results: The analysis revealed that rs1059394 TT and CT+TT genotype had significantly low glioma risk (TT to CC: OR = 0.71, 95% CI = 0.52–0.97, P = 0.03; CT+TT to CC: OR = 0.74, 95% CI = 0.55–0.99, P = 0.04). However, no significant difference was found between rs2847153 and glioma risk in any genetic model (P﹥0.05). In high-grade gliomas, the GA and GA+AA genotypes of rs2847153 made the majority of genotypes, compared with GG genotype (GA to GG: OR = 2.01, 95% CI = 1.39–2.91, P < 0.001; GA+AA to GG: OR = 1.78, 95% CI =1.25–2.54, P < 0.001). Moreover, online expression quantitative trait locus (eQTL) analysis indicated that these two polymorphisms may alter TYMS gene expression in transformed fibroblast cells.Conclusion: Our study provides evidence of the effect of TYMS rs1059394 on the susceptibility of glioma. In high-grade gliomas, compared with GG genotype, the GA and GA+AA genotypes of rs2847153 comprise a larger proportion.Keywords: TYMS, glioma, gene variant, susceptibility, case-control study
Yu-Han Hu, Shuai Ma, Xiang-Nan Zhang, Zhe-Ying Zhang, Hui-Fang Zhu, Ying-Hua Ji, Jian Li, Xin-Lai Qian, Yong-Xia Wang
Published: 4 October 2019
OncoTargets and Therapy, Volume 12, pp 8105-8115; doi:10.2147/ott.s223423

Abstract:Hypermethylation Of ADHFE1 Promotes The Proliferation Of Colorectal Cancer Cell Via Modulating Cell Cycle Progression Yu-Han Hu,1,* Shuai Ma,1,* Xiang-Nan Zhang,2 Zhe-Ying Zhang,1 Hui-Fang Zhu,1,2 Ying-Hua Ji,3 Jian Li,4 Xin-Lai Qian,1,2 Yong-Xia Wang1,2 1Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453000, People’s Republic of China; 2Department of Pathology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, People’s Republic of China; 3Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, People’s Republic of China; 4Department of Surgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yong-Xia Wang; Xin-Lai QianDepartment of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453000, People’s Republic of ChinaTel +86-15090325842; +86-13839073820Email [email protected]; [email protected]: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Studies have demonstrated that epigenetic modifications play essential roles in the development of CRC. ADHFE1 is a differentially expressed gene that has been reported to be hypermethylated in CRC. However, the role and mechanism of ADHFE1 in the proliferation of CRC remain unclear.Materials and methods: ADHFE1 expression was analyzed in CRC tissues by IHC and qRT-PCR, and the relationship between ADHFE1 expression and the clinicopathological parameters was analyzed. Cell proliferation were assessed by the in vitro and in vivo experimental models. GSEA assay was performed to explore the mechanism of ADHFE1 in the proliferation of CRC. Flow cytometry and Western blot were used to detect the activation of the cell cycle signaling. Bisulfite genomic sequence (BSP) assay was used to test the methylation degree of ADHFE1 gene promoter in CRC tissues.Results: Here, we verified that ADHFE1 was down-regulated and hypermethylated in CRC tissues. The down-regulation of ADHFE1 was correlated with poor differentiation and advanced TNM stage of CRC patients. And ADHFE1 expression restored when the CRC cell line SW620 was treated with the demethylating agent 5-Aza-CdR. Overexpression of ADHFE1 inhibited the proliferation of CRC, while ADHFE1 knockdown promoted the proliferation of CRC cells in vitro and in vivo. Moreover, ADHFE1 overexpression could induce a significant G1-S cell cycle arrest in CRC cells and vice versa.Conclusion: Hypermethylation of ADHFE1 might promote cell proliferation by modulating cell cycle progression in CRC, potentially providing a new therapeutic target for CRC patients.Keywords: ADHFE1, colorectal cancer, hyperthylation, proliferation, cell cycle
Yunfei Liu, Jiale Wang, Luo Dong, Li Xia, Hongwei Zhu, Zhiqiang Li, Xiao Yu
Published: 4 October 2019
OncoTargets and Therapy, Volume 12, pp 8207-8216; doi:10.2147/ott.s222703

Abstract:Long Noncoding RNA HCP5 Regulates Pancreatic Cancer Gemcitabine (GEM) Resistance By Sponging Hsa-miR-214-3p To Target HDGF
I-Hung Shao, Hung-Cheng Kan, Chung-Yi Liu, Po-Hung Lin, Kai-Jie Yu, See-Tong Pang, Chun-Te Wu, Cheng-Keng Chuang, Ying-Hsu Chang
Published: 4 October 2019
OncoTargets and Therapy, Volume 12, pp 8189-8196; doi:10.2147/ott.s214060

Abstract:Role Of Robot-Assisted Partial Nephrectomy For Renal Cell Carcinomas In The Purpose Of Nephron Sparing